Qiagen N.V.

QGEN

NL0015001WM6

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:09:26 2025-01-13 pm EST			5-day change	1st Jan Change
45.98 ^USD	+2.92%		+2.59%	+3.17%

11:03am	Qiagen Plans $300 Million Synthetic Share Repurchase	MT
Jan. 10	Qiagen Expands QIAcuity Digital PCR System's Capacity	MT

Qiagen Partners With McGill University for Microbiome Research

November 13, 2024 at 06:10 am EST

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Qiagen N.V.

Qiagen Plans $300 Million Synthetic Share Repurchase	05:03am	MT
Qiagen Expands QIAcuity Digital PCR System's Capacity	Jan. 10	MT
QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights from Biological Samples	Jan. 10	CI
Qiagen Gets U.S. Clearance for Gastrointestinal-Illness Test	Jan. 09	DJ
Qiagen Receives FDA Clearance for Gastrointestinal Panel Tests	Jan. 09	MT
QIAGEN Secures U.S. Clearance for First QIAstat-Dx Mini Gastrointestinal Panel to Support Year-round Outpatient Care	Jan. 09	CI
Morgan Stanley Downgrades QIAGEN to Equalweight From Overweight, Cuts Price Target to $48 From $50	Jan. 06	MT
Morgan Stanley Lifts Qiagen PT, Maintains Overweight Rating	Dec. 30	MT
Qiagen N.V. - Special Call	Dec. 16
QIAGEN Launches Ingenuity Pathway Analysis Interpret	Dec. 12	CI
Qiagen Reports Over 1,000 Placements of EZ2 Connect Instrument Globally	Dec. 05	MT
Qiagen N.V. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-05-2024 10:50 AM	Dec. 05
Qiagen Seeks Bolt-On Acquisitions	Dec. 04	CI
Qiagen N.V. Presents at Citi's 2024 Global Healthcare Conference, Dec-04-2024 02:30 PM	Dec. 04
Qiagen Plans to Open New Facility in Spain in 2026	Nov. 29	MT
QIAGEN Launches Novel Tools for Customizing Digital PCR Assays and NGS Panels for Microbial Analysis	Nov. 27	CI
Qiagen N.V. Presents at 6th Annual Wolfe Research Healthcare Conference 2024, Nov-20-2024 12:40 PM	Nov. 20
QIAGEN NV : Jefferies is Neutral	Nov. 20	ZD
Qiagen N.V. Presents at Jefferies London Healthcare Conference 2024, Nov-20-2024 09:00 AM	Nov. 20
Qiagen N.V. Presents at Stifel 2024 Healthcare Conference, Nov-19-2024 09:00 AM	Nov. 19
Qiagen Partners With McGill University for Microbiome Research	Nov. 13	MT
Qiagen, McGill University Enter Partnership Deal for Microbiome Research Development	Nov. 13	MT
Qiagen Collaborates with McGill University to Advance Microbiome Research	Nov. 12	CI
QIAGEN NV : UBS reiterates its Neutral rating	Nov. 11	ZD
Qiagen N.V., Q3 2024 Earnings Call, Nov 07, 2024	Nov. 07

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Employees

5,800

Sector

Biotechnology & Medical Research

Calendar

2025-02-10 - Q4 2024 Earnings Release (Projected)

More about the company